1. Merck to buy Pandion for $1.9B for its immune modulators — Biden looking beyond Woodcock or Sharfstein for FDA commmisioner — Former AveXis execs launch gene therapy startup See more on our front page news Stay updated with the latest pharma-related coronavirus news on our new page
    Dismiss Notice

Amedica and Zimmer soon to be one

Discussion in 'Zimmer' started by Boston745, Sep 20, 2017 at 12:18 PM.

?

How long until Zimmer acquires Amedica?

  1. 1 month

  2. End of year

  3. 2018

  4. 2019

  5. Never

Results are only viewable after voting.
  1. anonymous

    anonymous Guest

    Tell us more about 6.5 million dollar company nobody will buy lol!!! Talk about misinformation, you have speculation and consider it fact? You have shown to be innaccurate in all of your speculative statements so far. Next week this company will be worth 5 million dollars and you will have an excuse for this as planned. The internet is laughing at you, Zimmer is laughing at you, the SEC is now watching you.
     
  2. anonymous

    anonymous Guest

    Go home Dana, drunk and desperate still.
     
  3. anonymous

    anonymous Guest

    He couldn't get his job back now he is spamming the Zimmer board? LOL.
     
  4. anonymous

    anonymous Guest



    Hope the following information helps to support the theory of connections between Zimmer & Amedica:

    As hip replacement lawsuits were swamping the industry, even before 2010...

    From 2002 to 2013, Consumer’s Union found 578 recalls from six major manufacturers: Biomet, DePuy, Smith & Nephew, Stryker, Wright and Zimmer. Stryker had the most recalls with 231 and DePuy came in second with 150. These recalls came too late for tens of thousands of people who already received the problematic devices.​

    https://www.drugwatch.com/hip-replacement/recalls/

    Looks like it fits in the timeline, in 2011 (Zimmer was searching for new biomaterial to fix the issues):

    Zimmer is looking at purchasing Amedica flat out for their techology to bolster sales in spine through licensing and to purchase the next generation of hip and knee implants. You heard it here on TSB.​

    http://spineblogger.blogspot.com/2011/05/whos-next.html?m=1

    May 2013, Zimmer President of the Orthopedics Implant Division joined Orthopaedic Synergy, Inc. as a BOD

    The Board of Directors of Orthopaedic Synergy, Inc. ("OSI") whose subsidiary companies include OMNIlife science®, Inc., Enztec, Ltd., and Praxim, SA, have elected two experienced directors to their Board. Guy Mayer,

    https://www.prnewswire.com/news-rel...ions-to-the-board-of-directors-208198531.html

    President of the Orthopedics Implant Division - Zimmer Inc

    https://www.zoominfo.com/p/Guy-Mayer/382663

    Late December 2013 - Early 2014, OSI helped them to design prototype of femoral heads to initiate the biomechanical testing with a strategic partner.

    Our Total Hip Implant Product Candidates

    We have developed two designs of femoral heads for use in our total hip replacement product candidates. Our first design is a silicon nitride-coated metal femoral head, for total joint replacement, which we plan to develop with a medical device partner. The second design is a femoral head that is made from our solid MC2 silicon nitride and we are collaborating with Orthopaedic Synergy, Inc. to develop a total hip replacement product candidate using this design. These femoral heads are expected to articulate against a cross-linked polyethylene liner, fixed into a metal acetabular cup. We intend to initially advance our process to develop silicon nitride-coated femoral heads and then, together with a strategic partner, initiate biomechanical testing with our silicon nitride-coated femoral head for use in total hip replacement procedures to support a 510(k) submission to the FDA. If clearance is obtained, we intend to commercially launch products for use in total hip replacement by the second half of 2015. Although we have designs for solid silicon nitride components, we have not yet determined if we will pursue the development of these components.​

    In order to succeed in our joint commercialization efforts, we and OSI, and any future partners must execute effectively on all elements of a combined business plan, including continuing to establish sales and marketing capabilities, manage certified, validated and effective commercial-scale manufacturing operations, conduct product development and testing, and obtain regulatory clearances and approvals for our product candidate.​

    https://www.sec.gov/Archives/edgar/data/1269026/000119312514124269/d698775d10k.htm

    Who was/is that hidden strategic partner??? Look like they postponed the acquisition (as originally planned) to further testing the Si3N4 tech in other components like Spine, Dental, Knees, etc...

    Hence, early 2014, Amedica went IPO.

    Sometimes 2015 - 2016, they executed the biomechanical testing of 5 Millions cycles using Zimmer's latest vivacit-e-vitamin-e-highly-crosslinked-polyethylene

    SALT LAKE CITY, UT -- (Marketwired) -- 02/27/17 -- Amedica Corporation (NASDAQ: AMDA), an innovative biomaterial company which develops and manufactures silicon nitride as a platform for biomedical applications, announced today that Researchers from the Department of Orthopaedic Surgery of Tokyo Medical University (Shinjuku-ku, Tokyo, Japan) led by Professor Kengo Yamamoto MD PhD recently completed a five million cycle (Mc) comparative hip simulator study examining the wear behavior of an advanced highly cross-linked and vitamin E stabilized polyethylene (E1® Zimmer-Biomet, Warsaw, IN, USA) against two different types of ceramic femoral heads -- MC2®silicon nitride (Amedica Corporation, Salt Lake City, UT, USA) and BIOLOX®delta (CeramTec, Plochingen, Germany). BIOLOX®delta is currently considered the "gold standard" for ceramic femoral head materials. While the polyethylene wear loss induced by both types of ceramic heads was extremely small (< 0.60 mg/Mc), mean wear associated with MC2®silicon nitride heads was approximately 15% lower than the BIOLOX®delta components.​

    http://www.zimmerbiomet.com/medical...itamin-e-highly-crosslinked-polyethylene.html

    Fast Forward to 2017 - 2018, no more OSI involvement, only the hidden strategic partner!

    We are seeking a strategic partner to develop and commercialize our total joint replacement product candidates. We will be reliant on our strategic partners to develop and commercialize a total hip or knee joint replacement product candidate that utilizes silicon nitride-coated components, although we have not yet entered into an agreement with any strategic partner to develop products with these silicon nitride-coated components and may be unable to do so on agreeable terms. In order to succeed in our joint commercialization efforts, we and any future partners must execute effectively on all elements of a combined business plan, including continuing to establish sales and marketing capabilities, manage certified, validated and effective commercial-scale manufacturing operations, conduct product development and testing, and obtain regulatory clearances and approvals for our product candidate. If we or any of our strategic partners fail in any of these endeavors, or experience delays in pursuing them, we will not generate revenues as planned and will need to curtail operations or seek additional financing earlier than otherwise anticipated.

    https://www.sec.gov/Archives/edgar/data/1269026/000149315218002146/forms-1.htm

    Acquisition news is yet announced, hence they just mentioned "strategic partner" in general.

    As for Spine:

    Per below blog, even Amedica Spine Fusion CASCADE clinical trial was supervised by Zimmer Surgeons:

    https://amedicablog.wordpress.com/2017/09/12/zimmer-amedica-connections-via-personnel/
     
  5. anonymous

    anonymous Guest

    Everyday Amedicas stock price tanks it seems Dana gets more and more desperate with these funny ass spam posts. how much is this shithole Amedica worth now? 5 million? 4 million? Our new CEO just paid 3 million for Zimmer shares to get his full package. Hell, he alone could afford Amedica if he wanted it. How many shares of Amedica does Sonny Bal own? Do any of your named VP's at Amedica own anything? NO. Nobody believes in Amedica from the inside, that is a rotten company living off shareholders backs till bankruptcy. Now go be desperate on an Amedica forum somewhere,
     
  6. anonymous

    anonymous Guest

    Nailed it ^^^^. If Amedica goes bankrupt what does Sonny have to gain from the loan he gave Amedica? Food for Thought. Does he walk away happy is my question?
     
  7. anonymous

    anonymous Guest

    Good luck getting any type of price premium for a new material from the hospital. So what’s the advantage over something with some clinical history like ceramic? This just seems like a solution looking for a problem.
     
  8. anonymous

    anonymous Guest

    Not sure about the new financing deals but for now looks like he walks with the IP of Amedica. Looks like he set himself up with that north stadium loan if the company tanks and by the looks of it, it shouldn't be long.
     
  9. koko wawa

    koko wawa new user

    Joined:
    Feb 24, 2018
    Messages:
    6
    Likes Received:
    0
    Bal Bhajanjit already screwed all your lies, you look like a fool!
     
  10. anonymous

    anonymous Guest

    Scott aka boston745 - https://amedicablog.wordpress.com/

    If you have a tip or complaint involving the conduct listed - False or misleading statements about a company sec.gov/tcr

    Zimmer IR Please ask for - Barbara Goslee, Director, IR 574-371-9449 barb.goslee@zimmerbiomet.com

    Zimmer IR Please ask for - Derek Davis, Interim VP IR and VP Global Integration 574-372-4250 derek.davis@zimmerbiomet.com

    Zimmer Media Contact in case anyone writing a story about B745 scam. Monica Kendrick 574-372-4989 monica.kendrick@zimmerbiomet.com
     
  11. koko wawa

    koko wawa new user

    Joined:
    Feb 24, 2018
    Messages:
    6
    Likes Received:
    0
    Bal Bhajanjit plays a dirty game, he asked Boston to pump the stock, meanwhile he leaked info to his cronies tutes to sell, all of them sold at the same time because of leaked insider info
    Now step 2: Butcher retail investors by all kind of bad news, his favorite part
    Even if Zimmer buys AMDA later, Zimmer/Bhajanjit will be subject to lawsuits as they were conspiring against shareholders
     
  12. anonymous

    anonymous Guest

    Below, just a few excerpts from a long list is to answer the above quotes:
    • The stock weakness gives legitimacy to the contrived negative blogs. The idea is to create fear and uncertainty among investors by making all news events appear to be negatives and to fabricate new issues that the shorts hope will demoralize investors.
    • There are a number of bloggers who participate in these attacks. Many of these bloggers appear to work together and coordinate their negative attacks. It is striking that many of these people have connections to one another. Many of them were trained at a well-known blogging site that was founded by hedge fund people.
    • The situation quickly escalated. In the rebuttal, the blogger accused me of being stupid, deceitful and being paid by the Company to write positive comments.
    • The blogger was indifferent to truth and actually would make up information that was factually incorrect. When made aware that the information was wrong, he/she would ignore it and even repeat it in later blogs.

    From here:

    https://smithonstocks.com/illegal-n...rt-of-an-extensive-stock-manipulation-scheme/

    http://counterfeitingstock.com/CounterfeitingStock.html

    Know their methods:

    Blame the Management! Attack the stock!

    Attack the FACT poster; the researcher (Boston), trying to discredit his hard work! Trying to MUTE him! Because he is threatening their interests!

    Spread negative misinformation about the tiny company (Amedica)... with superior technologies that being bought out soon by a bigger medical device company (Zimmer)...based on so many pieces of evidence.

    etc...

    Now, to answer the quotes regarding, personnel & product development connections:

    [QUOTE="anonymous,...]Currently, a few Zimmer VPs at Amedica:

    https://www.linkedin.com/in/ryanjlong/

    https://www.linkedin.com/in/jamey-rottman/

    https://www.linkedin.com/in/dana-lyons-a23b9550/[/QUOTE]


    [QUOTE="anonymous,...]The Board of Directors of Orthopaedic Synergy, Inc. ("OSI") whose subsidiary companies include OMNIlife science®, Inc., Enztec, Ltd., and Praxim, SA, have elected two experienced directors to their Board. Guy Mayer,

    https://www.prnewswire.com/news-rel...ions-to-the-board-of-directors-208198531.html

    President of the Orthopedics Implant Division - Zimmer Inc

    https://www.zoominfo.com/p/Guy-Mayer/382663

    Late December 2013 - Early 2014, OSI helped them to design prototype of femoral heads to initiate the biomechanical testing with a strategic partner

    Per below blog, even Amedica Spine Fusion CASCADE clinical trial was supervised by Zimmer Surgeons:

    https://amedicablog.wordpress.com/2017/09/12/zimmer-amedica-connections-via-personnel/ [/QUOTE]

    In addition to personnel & product development connections, Zimmer & Amedica have connections via business partners as well:

    https://seekingalpha.com/article/41...thalmann-2017-healthcare-conference-slideshow

    On slide 27/30, NGK billion-dollar company partner with Amedica and:

    http://www.jmdm.co.jp/eng/corporate/partners

    and...From NGK & Japan Medical Dynamic Marketing Inc business alliance:

    Notice of Capital and Business Alliance with Japan Medical Dynamic Marketing Inc. and Acquisition of Stock Shares (Equity Method Affiliate)​

    https://www.ngkntk.co.jp/english/news/upload/20160420_e.pdf

    and....since 2009, Zimmer & JMDM are parnters!

    In November 2009, we concluded a joint sales agreement with Zimmer K.K. to further strengthen our product lineup and promote joint sales, thus expanding our market share at the same time.​

    http://www.jmdm.co.jp/eng/products

    Furthermore,

    On September 22, 2017, Zimmer Biomet G.K. (the “Borrower”), a wholly-owned subsidiary of Zimmer Biomet Holdings, Inc. (the “Company”), entered into (i) a Term Loan Agreement (the “New Term Loan Agreement”) with Sumitomo Mitsui Banking Corporation (“SMBC”), for a new ¥21.3 billion term loan,​

    https://www.sec.gov/Archives/edgar/data/1136869/000119312517297866/d464265d8k.htm

    The loan amount is around $189 millions USD.

    What is cooking in Japan? Why such a big loan? Some forms of business preparations to profit in Japan Market!

    Coincidentally, or jointly planned, whatever you put it, Amedica's latest business update:

    Progress toward regulatory clearance in Japan.
    https://investors.amedica.com/press-releases/detail/113/amedica-provides-business-update

    &

    Even new Spine HQ:

    http://ozarch.com/2017/10/zimmer-biomet-spine-opens-new-headquarters-westminster-colorado/

    Amedica has mature Spine products & other products are being developed too. See all the clicks between both?

    Zimmer Spine business has tons of room to grow, ranking #5 in the industry (look at page 25):

    https://www.sec.gov/Archives/edgar/data/1136869/000119312517065632/d285470d10k.htm

    and the job openings at the new Spine HQ (expanding):

    https://www.indeed.com/jobs?q=Zimmer+Biomet&rbl=Westminster,+CO&jlid=6f64b78298d21bb1

    & Of course...

    Most importantly, Zimmer's CEO Hanson's own words:

    "In terms of our innovation capabilities, Zimmer Biomet is uniquely positioned to leverage platform technologies across our entire portfolio, including advanced proprietary materials and surgical robotics applications. As a company, we plan to build on this foundation. We will have an unwavering emphasis on patient safety and quality excellence, creating an engaged and innovative workplace and working to position the company to deliver top quartile total shareholder returns."

    "That said, based on everything I've learned, I am more confident than ever that this business is going to turn around. Although the pacing may not be what you expected or hoped for, I'm 100% confident that the end game is going to be something you're going to be very happy about. So thanks so much. I appreciate you joining the call today. I'm looking forward to connecting with you between now and earnings call, I’m sure, through various events, but really looking forward to connecting on the first quarter earnings call as we give guidance for 2018. Thanks so much."

    https://seekingalpha.com/article/41...-results-earnings-call-transcript?part=single
    It is indeed slow pace. Slowly phasing out the flop biomaterial (Trabecular Metal), while testing & securing the newer advanced biomaterial Si3N4 remotely! Smart move by Zimmer!
     
  13. anonymous

    anonymous Guest

    Talk about yearly guidance...why there is no guidance for 2018 yet??? Still can't figure out how much Amedica tech will help Zimmer to boost up revenue in 2018!

    Full Year 2012 Report:

    The Company expects full-year revenues for 2013 to increase between 2.5% and 4.5% on a constant currency basis. ​

    https://www.sec.gov/Archives/edgar/data/1136869/000119312513031002/d475932dex991.htm

    Full Year 2013 Report:

    The Company expects full-year revenues for 2014 to increase between 3.0% and 5.0% on a constant currency basis. ​

    https://www.sec.gov/Archives/edgar/data/1136869/000119312514027376/d667348dex991.htm

    Full Year 2014 Report, NO FULL YEAR GUIDANCE for 2015:

    This guidance does not contemplate the projected accretion associated with the pending Biomet merger. Guidance for the full year 2015 will be provided after the closing of the transaction with Biomet, expected before the end of this quarter.

    https://www.sec.gov/Archives/edgar/data/1136869/000119312515024461/d862570dex991.htm

    Full Year 2015 Report:

    The Company expects constant currency revenue for the full year 2016, as compared to adjusted pro forma 2015 revenue, to increase between 1.5% and 2.5%.​

    https://www.sec.gov/Archives/edgar/data/1136869/000119312516440674/d95315dex991.htm

    Full Year 2016 Report:

    The Company expects constant currency revenue for full-year 2017, as compared to 2016 revenue, to increase between 3.7% and 4.7%

    https://www.sec.gov/Archives/edgar/data/1136869/000119312517024528/d338232dex991.htm

    Full Year 2017 Report, NO FULL YEAR GUIDANCE FOR 2018, WHY? Only talked about Q1 2018 Guidance (there must be a good reason!):

    For the first quarter of 2018, the Company expects revenue in the range of $1.955 billion to $1.995 billion, representing a change of negative 1.0% to positive 1.0% compared to the prior year period, and negative 4.0% to negative 2.0% on a constant currency basis compared to the prior year period, inclusive of negative impact related to approximately one less billing day compared to the prior year period.

    Additionally, the Company expects its diluted earnings per share for the first quarter of 2018 to be in a range of $0.73 to $0.88, and in a range of $1.84 to $1.91 on an adjusted basis.

    https://www.sec.gov/Archives/edgar/data/1136869/000156459018001032/zbh-ex991_6.htm

    What event was Hanson referring to & hinting the investors? Sounds exciting, isn't it? & what was the hold back on the 2018 Full Year Revenue Guidance disclosure? Why so much misleading information about Amedica by some individuals here? Even create a new alias to post to distort the FACT! What is cooking between Zimmer & Amedica? How big the transaction will be?

    ALL FACT! All SOURCED information with links to verify!
     
  14. koko wawa

    koko wawa new user

    Joined:
    Feb 24, 2018
    Messages:
    6
    Likes Received:
    0
    Your fellow Indian crook Bhajanjit Bal says good job Boston
    As you are still pumping with the same spirit after it lost 99% in 3 years
    You will get a good treat after the dilution
     
  15. koko wawa

    koko wawa new user

    Joined:
    Feb 24, 2018
    Messages:
    6
    Likes Received:
    0
    Bhajanjit Bal send you his best regards and promise it be only 3 dilutions and 2 RSs before the M&A
     
  16. anonymous

    anonymous Guest


    Amedica has 0% market share on their only 2 products???? No revenue? Toxic Financing and NO FDA approval of new products or even the studies needed to get an approval. (as we see from recent denials) Amedica barely has 30 employees left after Sonny Bal fired half to save the company in 2016.
    Biomet was a merger with over 10,000 biomet employees and mass amounts of real estate. The market share issues were solved by selling off ZUK uni knee ect. There is absolutly no reason or no way in hell that Zimmer has been trying to buy Amedica since 2011. Common sense would tell you Sonny Bal plans to run the show until he is physically removed from amedicas office for not having the shareholder meeting that would get his vote out of Amedica. Amedica is clinging to life and those who have lost their life savings invested in Amedica are trying to convince others that Zimmer has been slowly merging since 2011.
     
  17. anonymous

    anonymous Guest

    More grasping & trying to distort the fact again from market makers (market manipulators), hedge funds managers & the et al...blah blah blah...

    As a matter of FACT, Amedica by itself will not be able to compete with big players out there & will not be able to gain meaningful market share on their own. Their MAIN JOB was to VALIDATE the Si3N4 biomaterial technologies for medical device applications (Spine, Hips, Knees, Dental, etc...). So their previous years, they focused on testing tech & testing the market & only pulled in tiny revenue...but not anymore. With the implementation of pre-acquisition talent integration, after 3 plus VPs from Zimmer joined them (as black ops), their revenue is back on track again:

    https://amedicablog.wordpress.com/2018/02/22/q4-2017-revenue/

    #s won't lie! Based on the calculations, with a sale team of less than 20 people (you said 30+ total employees, which is correct), $20 mils revenue in 2017 (4Q = $9 mils to $12 mils = 300% - 400% increased - compares to 3Q' 2017 & 4Q' 2016). This is evidence of the initial synergy at work from both (Zimmer & Amedica). Imagine the level of revenue can be generated once the tech is taken over by Zimmer & fully integrated with Zimmer's vast resources of sale channels & customer relationships. In addition, Japan region clearance is imminent as well & will bring in nice chunk of revenue too, not including revenue from future products. The total revenue will skyrocket..lucrative revenue streams for Zimmer later in time... Amedica has the tech... Zimmer has the resource to fully unlock the potential of the tech. PERFECT MARRIAGE! Why the hate man? Hence, Hanson & his teams can't give proper guidance for the full year of 2018 yet (or could be a strategic reason - not leaking any info. before the announcement of the merger). See the connections of the dots? Of course you do, but I know you just want to distort the fact. You can attack the target company, but you can't stop the plans (for years) that Zimmer is trying to own this tech (await the validation on the tech, which is now is pretty much done).

    Now, look at the job opening at Amedica last few weeks:

    https://www.indeed.com/viewjob?jk=ea4a52e1de37ab4d&from=companyalert&tk=1c7as0acvbqsnej5

    See the job duties? The position is to assist & support the sales team - increase in sales - higher revenue! Again, the increase in revenue only can be done by using the resources from Zimmer through their 3 black ops VP at Amedica. Now back to reply to your grasping on "Sonny Bal fired half to save the company in 2016."...Please allow me to LMAO again! If AMDA is going solo, Sonny will reinstate the important positions like CFO, Controller, IR team, etc...right? Why didn't they? Because Zimmer already has:

    CFO - Dan Florin

    Controller - Tony Collins

    IR - Derek Davis

    http://www.zimmerbiomet.com/corporate/about-zimmer-biomet/leadership.html

    These reluctant positions are not necessary at Amedica as they are preparing themselves to be the bride to marry the groom, Zimmer! Also, the link also mentioned about Amedica inventory level will only last until end of 2Q' 2018. More sign of not going solo. This plays well with Hanson's 4Q' 2017 CC about connect with investors...through various events by then. It means once the deal is closed (announce March - April, close before 2Q ends), Zimmer will out source the manufacturing process of Si3N4 products with external vendors. See how the pieces of puzzle are clicked to each other? Complete analysis of Zimmer's 4Q' 2017 CC:

    https://amedicablog.wordpress.com/2018/02/03/zimmers-q4-conference-call/

    Now back to revenue discussion from the provided link.

    Amedica with a sales team of less than 20, the revenue ...

    In 2018, minimum est. $4 - $5 mils / month, which is roughly $50 - 60 mils / year not including the future revenue from Japan & other products, & regions...At this level, they are possibly at break even point or even starting to profit already. It is possibly will be an accretive acquisition for Zimmer:

    https://www.investopedia.com/terms/a/accretiveacquisition.asp

    as oppose to LDRH acquisition 2016 - which was a dilutive acquisition. LDRH only helped Zimmer to pull in roughly $170 mils per year in Spine business even after 5 quarters of integration (LDHR revenue - prior acquisition was $160 mils per year already - lack of growth potential). Not helping much after all & Zimmer paid $1 bil to acquire them.

    The superior tech from 30-employee tiny company transfers over to a company that is 600 times bigger (Zimmer has around 19K employees). Can you imagine how much extra revenue this tech will help Zimmer in the long term???

    Regarding future products & FDA approvals, Zimmer has the resource & political influences to easily obtain many future regulatory approvals for sure. Let's Hanson & his team worry about this.

    Regarding the grasping on "Zimmer has been slowly merging since 2011", yet again, Zimmer learned their mistake on Trabecular Metal, isn't it??? What make you think they don't want to make 1000000000000% sure that Si3N4 will not be like another TM again...hence the long plans for years - fully tested the tech first!!! Most importantly, the time to pull the trigger is close - based on Hanson's own words on 4Q' 2017 CC.
     
  18. anonymous

    anonymous Guest

    Kids, this is what happens when you make bad decisions. Don't spend your life savings on a penny stock scam. You will end up like Scott aka Boston745. The SEC gets reports everyday for his illegal stock pumping, only a matter of time before Zimmer spanks him also. He bashes Trabecular Metal, talks about backdoor payments to Sonny bal other company's from Zimmer. Making Zimmer look real stupid for sure. A 6.5 million dollar company telling Zimmer what they are doing wrong. What a joke. Spank this fool

    Scott aka boston745 - https://amedicablog.wordpress.com/

    If you have a tip or complaint involving the conduct listed - False or misleading statements about a company sec.gov/tcr

    Zimmer IR Please ask for - Barbara Goslee, Director, IR 574-371-9449 barb.goslee@zimmerbiomet.com

    Zimmer IR Please ask for - Derek Davis, Interim VP IR and VP Global Integration 574-372-4250derek.davis@zimmerbiomet.com

    Zimmer Media Contact in case anyone writing a story about B745 scam. Monica Kendrick 574-372-4989monica.kendrick@zimmerbiomet.com
     
  19. anonymous

    anonymous Guest

    Dana is DRUNK and HIGH this time. They must be counting down the days until bankruptcy over at amedica. What a joke. An entire industry sees the fluff yet one investor cant get over the fact he lost everything on a bad gamble.
     
  20. anonymous

    anonymous Guest

    The senior accountant they hired last year is now their controller, FYI.

    As far as Zimmer waiting for Si3N4 to be validated, that's so obvious and the evidence is there in this basic timeline.

    May 2011- it was said Zimmer was looking at acquiring Si3N4.
    May- Dec 2011, Amedicas Cascade trial was designed.
    Dec 2011- Cascade trial begins recruiting with Dr. Arts & Dr. Wolf overseeing the trial; both surgeon consultants for Zimmer.

    This is exactly what you would expect to see if Zimmer wants to validate the tech first especially tapping surgeons they can trust to oversee the trials.

    Jan 2012 - Zimmer taps their surgeon consultant Dr. Bal to join Amedicas BOD. Now Zimmer has 2 members on Amedicas board.
    Sept 2013 - Cascade trial officially begins and Amedica prepares IPO to use public funds to validate tech.
    March 2014 - Snap Trial begins
    Aug 2014 - Chairman Dr. Link steps down for health reasons. Dr. Bal becomes Chairman. Zimmer maintains influence on board.
    Sept 2014 - cascade completes 1 year milestone
    Oct 2014 - Dr. Bal takes over as CEO as well as Chairman. Zimmer increases its influence on Amedica.
    March 2015 - Snap trial completed 1 year milestone.
    July 2015 - Letter of Intent with Amedica is signed as cascade trial comes to a close, 2 year milestone.
    Sept 2015 - Cascade trial completed
    March 2016 - Snap trial completed

    When Zimmer merged with Implex it signed an exclusive distribution deal August 2000. 3 years later and 7 product candidates later, Zimmer announces merger with Implex Nov 2003.
    How many product candidates are in development at Amedica? Spine, Hip, Knee, dental with more possible. The similarities between Amedica and Implex are uncanny but with Amedica Zimmer had to be far more cautious because Trabecular Metal cost them with its multiple recalls, poor performance in some areas, lawsuits, & hurt their public image. Do people think its a coincidence Dvorak was tapped as CEO, a lawyer, in 2007 before the recalls and lawsuits hit the media? I know I don't.
    Yes as previous poster said Zimmer has had to make every effort to ensure Si3N4 is properly tested before taking on another ortho material. From what I've seen Si3N4 is hands down better than Trabecular Metal.